?Product Name?: Ethyl 7-Chloro-1-cyclopropyl-8-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylate (Ozenoxacin Intermediate)
?CAS No.?: 103877-51-6

?? ?Product Overview?
A high-purity pharmaceutical intermediate essential for synthesizing ?Ozenoxacin? (CAS 245765-41-7), a ?non-fluorinated quinolone antibiotic? approved for treating bacterial skin infections like impetigo and acne. With a purity of ?≥98%? (HPLC-certified), it ensures reliable performance in API manufacturing and R&D for novel antibacterial agents targeting drug-resistant pathogens. Available in bulk quantities (1kg–25kg) with flexible packaging options.

?? ?Key Advantages?
? ?High Purity?: ≥98% (HPLC/GC-certified), minimizing impurities in API synthesis.
?? ?Scalable Supply?: Custom packaging (1kg, 5kg, 25kg) for industrial and laboratory use.
?? ?Critical Role?: Core building block for Ozenoxacin, a first-in-class non-fluorinated antibiotic with expanding therapeutic applications.

?? ?Applications?

1. ?Antibiotic Production?: Primary intermediate for Ozenoxacin API synthesis.

2. ?R&D of Quinolones?: Supports development of next-generation antibacterial drugs.

3. ?Global Export?: Widely traded in pharmaceutical and chemical reagent markets.

?? ?Quality Certification?

• ?Testing Standards?: HPLC, GC, NMR, and mass spectrometry.

• ?Compliance?: Meets ISO 9001 and industrial-grade specifications.

?? ?Market Trends?
The demand for Ozenoxacin intermediates is growing due to its ?patent expirations? (2024) and rising global focus on antibiotic resistance. The topical antibacterial market is projected to grow at ?6.5% CAGR? (2025–2030), driven by increasing skin infection cases. Asia-Pacific remains a key production hub, with suppliers offering ?GMP-ready batches? gaining competitive advantages.